## Åukasz SÄďek

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2100364/publications.pdf

Version: 2024-02-01

304743 155660 4,321 67 22 55 h-index citations g-index papers 70 70 70 6949 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia, 2012, 26, 1908-1975.	7.2	738
2	EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia, 2012, 26, 1986-2010.	7.2	668
3	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	7.2	527
4	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia, 2017, 31, 2094-2103.	7.2	486
5	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	7.2	393
6	Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood, 2017, 129, 347-357.	1.4	323
7	Quality assessment program for <scp>E</scp> uro <scp>F</scp> low protocols: Summary results of fourâ€year (2010â€'2013) quality assurance rounds. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 145-156.	1.5	144
8	Chalcones Enhance TRAIL-Induced Apoptosis in Prostate Cancer Cells. International Journal of Molecular Sciences, 2010, 11, 1-13.	4.1	120
9	Enhanced TRAIL-mediated apoptosis in prostate cancer cells by the bioactive compounds neobavaisoflavone and psoralidin isolated from Psoralea corylifolia. Pharmacological Reports, 2011, 63, 139-148.	3.3	94
10	Flow cytometric immunobead assay for the detection of BCR–ABL fusion proteins in leukemia patients. Leukemia, 2009, 23, 1106-1117.	7.2	75
11	Leukemia surfaceome analysis reveals new disease-associated features. Blood, 2013, 121, e149-e159.	1.4	63
12	Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia. Leukemia, 2018, 32, 874-881.	7.2	44
13	Biallelic loss of <i>CDKN2A</i> is associated with poor response to treatment in pediatric acute lymphoblastic leukemia. Leukemia and Lymphoma, 2017, 58, 1162-1171.	1.3	43
14	Fluorochrome choices for multi-color flow cytometry. Journal of Immunological Methods, 2019, 475, 112618.	1.4	43
15	Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia. Journal of Immunological Methods, 2019, 475, 112429.	1.4	40
16	Detailed immunophenotyping of Bâ€cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection. British Journal of Haematology, 2017, 178, 257-266.	2.5	37
17	<i>PTEN</i> abnormalities predict poor outcome in children with Tâ€eell acute lymphoblastic leukemia treated according to ALL ICâ€BFM protocols. American Journal of Hematology, 2019, 94, E93-E96.	4.1	36
18	EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets. Journal of Immunological Methods, 2019, 475, 112662.	1.4	35

#	Article	IF	CITATIONS
19	DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL. Leukemia, 2012, 26, 367-371.	7.2	31
20	The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: How different are they from their normal counterparts?., 2014, 86, 329-339.		30
21	Flow cytometric immunobead assay for fast and easy detection of PML–RARA fusion proteins for the diagnosis of acute promyelocytic leukemia. Leukemia, 2012, 26, 1976-1985.	7.2	27
22	The effects of obesity on CD47 expression in erythrocytes. Cytometry Part B - Clinical Cytometry, 2017, 92, 485-491.	1.5	27
23	Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instruments. Journal of Immunological Methods, 2019, 475, 112680.	1.4	24
24	An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. Cancers, 2021, 13, 6148.	3.7	24
25	Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay. Best Practice and Research in Clinical Haematology, 2010, 23, 333-345.	1.7	23
26	The influence of LTS-4, a saponoside from Lysimachia thyrsiflora L., on human skin fibroblasts and human melanoma cells. Cellular and Molecular Biology Letters, 2008, 13, 585-98.	7.0	20
27	Comprehensive Investigation of miRNome Identifies Novel Candidate miRNA-mRNA Interactions Implicated in T-Cell Acute Lymphoblastic Leukemia. Neoplasia, 2019, 21, 294-310.	5.3	19
28	BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients. Blood Cells, Molecules, and Diseases, 2013, 50, 33-38.	1.4	17
29	Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study. Modern Pathology, 2021, 34, 59-69.	5.5	15
30	Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions. Oncotarget, 2018, 9, 25971-25982.	1.8	13
31	Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL. Scientific Reports, 2016, 6, 29427.	3.3	11
32	Surface Expression of CRLF2 Protein Is Associated with Lower Minimal Residual Disease (MRD) Among Children with IKZF1-deleted Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 2400-2400.	1.4	10
33	Infant acute bilineal leukemia. Leukemia Research, 2009, 33, 1005-1008.	0.8	9
34	<i>GATA3</i> germline variant is associated with <i>CRLF2</i> expression and predicts outcome in pediatric Bâ€cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 619-626.	2.8	9
35	The influence of fixation of biological samples on cell count and marker expression stability in flow cytometric analyses. Central-European Journal of Immunology, 2020, 45, 206-213.	1.2	9
36	Altered neutrophil immunophenotypes in childhood B-cell precursor acute lymphoblastic leukemia. Oncotarget, 2016, 7, 24664-24676.	1.8	8

#	Article	IF	CITATIONS
37	Multicolor flow cytometry immunophenotyping and characterization of aneuploidy in pediatric B-cell precursor acute lymphoblastic leukemia. Central-European Journal of Immunology, 2021, 46, 365-374.	1.2	8
38	Prognostic significance of <i>IKZF1</i> deletions and IKZF1 <sup>plus</sup> profile in children with Bâ€cell precursor acute lymphoblastic leukemia treated according to the ALLâ€IC BFM 2009 protocol. Hematological Oncology, 2022, 40, 430-441.	1.7	8
39	Flow cytometric minimal residual disease assessment in Bâ€cell precursor acute lymphoblastic leukaemia patients treated with CD19â€targeted therapies — a EuroFlow study. British Journal of Haematology, 2022, 197, 76-81.	2.5	8
40	Assessment of selected B cells populations in the workers of X-ray departments. International Journal of Occupational Medicine and Environmental Health, 2014, 27, 467-73.	1.3	7
41	Machine Learning Based Analysis of Relations between Antigen Expression and Genetic Aberrations in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia. Journal of Clinical Medicine, 2022, 11, 2281.	2.4	7
42	Immunoglobulin/T-cell receptor gene rearrangements in the diagnostic paradigm of pediatric patients with T-cell acute lymphoblastic leukemia. Leukemia and Lymphoma, 2012, 53, 1425-1428.	1.3	6
43	Secondary acute monocytic leukemia positive for 11q23 rearrangement in Nijmegen breakage syndrome. Pediatric Blood and Cancer, 2014, 61, 1469-1471.	1.5	4
44	Expression of Chemokine Receptors on Peripheral Blood T Cells in Children with Chronic Kidney Disease. Mediators of Inflammation, 2015, 2015, 1-8.	3.0	4
45	Costâ€effective screening of <i><scp>DNMT</scp>3A</i> coding sequence identifies somatic mutation in pediatric Tâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2017, 99, 514-519.	2.2	4
46	Perforin gene variation influences survival in childhood acute lymphoblastic leukemia. Leukemia Research, 2018, 65, 29-33.	0.8	4
47	Advantages and Limitations of SNP Array in the Molecular Characterization of Pediatric T-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2020, 10, 1184.	2.8	4
48	Mixed phenotype acute leukemia: Biological profile, clinical characteristic and treatment outcomes: Report of the populationâ€based study. European Journal of Haematology, 2020, 105, 85-93.	2.2	4
49	Czy leczenie inhibitorami DPP-4 ma wpÅ,yw na subpopulacje limfocytów u chorych na cukrzycÄ™ typu 2?. Endokrynologia Polska, 2014, 65, 78-82.	1.0	3
50	Impact of Pre-Analytical and Analytical Variables Associated with Sample Preparation on Flow Cytometric Stainings Obtained with EuroFlow Panels. Cancers, 2022, 14, 473.	3.7	3
51	Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome. Cancers, 2022, 14, 3088.	3.7	3
52	Subpopulacje limfocytów T i komórek NK we krwi obwodowej u zdrowych dzieci w wieku 3–19 lat. Pediatria Polska, 2011, 86, 123-132.	0.2	2
53	Expression Patterns of Coagulation Factor XIII Subunit A on Leukemic Lymphoblasts Correlate with Clinical Outcome and Genetic Subtypes in Childhood B-cell Progenitor Acute Lymphoblastic Leukemia. Cancers, 2020, 12, 2264.	3.7	2
54	Subpopulacje limfocytów B we krwi obwodowej u dzieci zdrowych. Pediatria Polska, 2013, 88, 500-507.	0.2	1

#	Article	IF	CITATIONS
55	Chemokine receptors on peripheral blood T lymphocytes in children on peritoneal dialysis. Peritoneal Dialysis International, 2021, 41, 194-201.	2.3	1
56	Gene expression of ASNS, LGMN and CTSB is elevated in a subgroup of childhood BCP‑ALL with PAX5 deletion. Oncology Letters, 2019, 18, 6926-6932.	1.8	1
57	Multiomics to investigate the mechanisms contributing to repression of <i>PTPRC</i> and <i>SOCS2</i> in pediatric Tâ $\in$ ALL: Focus on miRâ $\in$ 363â $\in$ 3p and promoter methylation. Genes Chromosomes and Cancer, 0, , .	2.8	1
58	Zastosowanie cytometrii przepÅ,ywowej do wstÄ™pnej diagnostyki nieziarniczych chÅ,oniaków zÅ,oÅ›liwych u dzieci. Pediatria Polska, 2007, 82, 713-721.	0.2	0
59	Flow Cytometric Detection of BCR-ABL Fusion Proteins in Leukemia Patients Via An Immunobead Assay. Blood, 2008, 112, 2533-2533.	1.4	O
60	Prognostic Value of Immunophenotype In Infant ALL – Results of the INTERFANT'99 Study. Blood, 2010, 116, 2700-2700.	1.4	0
61	Proteomic Exploration of the Cell Surface Landscape Reveals New Leukemia Associated Features Blood, 2012, 120, 2506-2506.	1.4	O
62	Heterogeneity Of CXCR4 Expression In Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2013, 122, 4952-4952.	1.4	0
63	Heterogeneity Of CXCR4 Expression In Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2013, 122, 4652-4652.	1.4	O
64	Recovery of the Normal B-Cell Compartment in Children Treated for B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3792-3792.	1.4	0
65	Euroflow-Based Immunophenotypic Characterization of CD34+ Cell Compartment in Juvenile Myelomonocytic Leukemia (JMML): A New Tool for Differential Diagnosis. Blood, 2016, 128, 3127-3127.	1.4	O
66	Polymorphic Variant in GATA3 gene Is a Hallmark of PAR1-Deleted BCP-ALL and Associates with Poor Prognosis Among Pediatric Patients Treated with the BFM Backbone Protocols. Blood, 2016, 128, 1742-1742.	1.4	0
67	Abstract 3324: Optimizing the therapeutic potential of tyrosine kinase inhibitors in chemo-immunotherapy of B-cell acute lymphoblastic leukemia involving rituximab. Cancer Research, 2022, 82, 3324-3324.	0.9	O